Increased incidence of miscarriage with efavirenz use

HIV Treatment Bulletin - Vol. 8, No. 8/9, August-September 2007

Polly Clayden, HIV i-Base

Despite being contraindicated in pregnancy an increasing number of women are becoming pregnant while receiving efavirenz-containing regimens.

A poster authored by Esau Joao and co-workers from the Hospital dos Servidores do Estado, Rio de Janeiro, Brazil, reported findings from a case note review to evaluate adverse pregnancy outcomes after exposure to efavirenz during the first trimester among women in their cohort.

The authors found 969 women had received any ARV prophylaxis or treatment in pregnancy between January 1996 and December 2006. 19.6% became pregnant while receiving ART. 776 women were unexposed at conception, 47 received mono or dual therapy with nucleosides, 36 ART with efavirenz and 107 women received other ART regimens. The median duration of exposure to efavirenz and other ART regimens were 13 and 19 weeks respectively.

The overall incidence of miscarriage in this cohort was 13/942 (1.38%).

There was 0.4% incidence of miscarriage among women receiving no ARTat conception; 2.1% with mono or dual nucleosides; 11.1% with efavirenz-containing ART and 4.8% with other ART, p<0.005.

Additionally, the authors reported 19/874 (2.2%) congenital abnormalities (background population in Rio de Janeiro in 2004, 0.8%), 17 occurred in infants born to women without any ARV exposure at conception.

Two birth defects were observed in infants born to women receiving ARTin the first trimester: one infant exposed to NVP+3TC+ d4T was born with patent foramen ovale, pulmonary valve stenosis and mitral valve hypoplasia and another exposed to AZT+ 3TC+EFV was born with pulmonary valve stenosis.

The authors suggested that the higher rate (11.1%) of miscarriage that occurred among women receiving efavirenz at conception in this cohort could “actually represent early congenital malformations.”

Comment

These data should be treated with extreme caution. The miscarriage rate reported from this notes review is extremely low (1.38%). It is generally thought that approximately 30% of conceptions are miscarried.

The potential for biased reporting is very high and this is more likely to be seen with efavirenz than other antiretroviral drugs.

Although the congenital anomaly rate is reported to be more than twice the background for Rio de Janeiro (2.2% v 0.8%) the later figure is only about one third of the normally cited of congenital malformations and 2.2% is a more realistic figure.

Ref: Joao E, Calvert G, Sidi L et al. Increased incidence of spontaneous abortion during first trimester exposure to efavirenz. IAS Conf HIV Pathog Treat 2007 Jul 22-25;4th: Abstract No. TUPEB113.

2007-08-10
IB070808-17

©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.